Nkarta (NASDAQ:NKTX) Price Target Lowered to $11.00 at Stifel Nicolaus

Nkarta (NASDAQ:NKTX) had its target price lowered by Stifel Nicolaus from $12.00 to $11.00 in a research note issued to investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target points to a potential upside of 451.38% from the stock’s current price.

Other analysts also recently issued research reports about the company. Wall Street Zen upgraded Nkarta from a “sell” rating to a “hold” rating in a research report on Saturday, October 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nkarta in a report on Friday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Nkarta in a research note on Wednesday, August 13th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $13.25.

Nkarta Stock Performance

NASDAQ:NKTX traded up $0.04 during mid-day trading on Tuesday, reaching $2.00. The stock had a trading volume of 166,818 shares, compared to its average volume of 932,107. The stock has a market capitalization of $141.70 million, a P/E ratio of -1.35 and a beta of 0.86. The firm has a 50 day moving average price of $2.14 and a two-hundred day moving average price of $2.01. Nkarta has a one year low of $1.31 and a one year high of $3.40.

Nkarta (NASDAQ:NKTX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.32) by $0.03. Research analysts forecast that Nkarta will post -1.7 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Jane Street Group LLC grew its holdings in Nkarta by 118.7% during the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock valued at $247,000 after purchasing an additional 852,559 shares during the period. Monaco Asset Management SAM purchased a new position in shares of Nkarta during the 1st quarter valued at about $1,496,000. Alyeska Investment Group L.P. grew its stake in shares of Nkarta by 54.7% during the 1st quarter. Alyeska Investment Group L.P. now owns 2,064,956 shares of the company’s stock valued at $3,800,000 after acquiring an additional 730,260 shares during the period. AWM Investment Company Inc. increased its holdings in Nkarta by 150.0% in the 1st quarter. AWM Investment Company Inc. now owns 1,000,000 shares of the company’s stock worth $1,840,000 after acquiring an additional 600,000 shares in the last quarter. Finally, AQR Capital Management LLC raised its stake in Nkarta by 300.5% during the 1st quarter. AQR Capital Management LLC now owns 672,078 shares of the company’s stock worth $1,237,000 after acquiring an additional 504,272 shares during the period. 80.54% of the stock is owned by hedge funds and other institutional investors.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.